Adial Pharmaceuticals, Inc. (ADIL)
Market Cap | 28.64M |
Revenue (ttm) | n/a |
Net Income (ttm) | -9.48M |
Shares Out | 13.65M |
EPS (ttm) | -0.82 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 21 |
Last Price | $1.99 |
Previous Close | $1.99 |
Change ($) | 0.00 |
Change (%) | 0.00% |
Day's Open | 2.00 |
Day's Range | 1.98 - 2.04 |
Day's Volume | 149,448 |
52-Week Range | 1.05 - 3.03 |
News
CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the dev...
CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for ...
ONWARD™ Trial Remains on Track to be Fully Enrolled During Q2 2021 CHARLOTTESVILLE, VA / ACCESSWIRE / December 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage bio...
About ADIL
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development of treatment for addictions. Its lead product is AD04, a selective serotonin-3 antagonist for the treatment of alcohol use disorder. The company was founded in 2010 and is based in Charlottesville, Virginia.
Industry Biotechnology | IPO Date Jul 30, 2018 |
CEO William B. Stilley III, M.B.A., MBA | Employees 3 |
Stock Exchange NASDAQ | Ticker Symbol ADIL |